Septerna, Inc. SEPN 深 沪
等待开盘 09-20 09:30:00 美东时间
15.70
-0.240
-1.51%
华盛通- 最 高16.12
- 今 开15.99
- 成交量 65.35万股
- 最 低 15.50
- 昨 收 15.94
- 总市值 7.00亿
- 52周最高 28.99
- 市盈率 静 --
- 换手率 1.47%
- 52周最低 4.17
- 委 比 -87.78%
- 总股本 4455.83万
- 历史最高 28.99
- 量 比 3.66
- 振 幅 3.89%
- 历史最低 4.17
- 每 手 1
- 风险率 6.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多减肥药巨头中场战事，国产GLP-1「围剿」司美
原标题：减肥药巨头中场战事，国产GLP-1「围剿」司美 新官上任三把火。在履新诺和诺德（NVO.US）CEO一个月后，马齐亚尔·迈克·杜斯特达（Maziar...
09-15 16:32
SA Asks: Which biotechs could be acquired by year's end?
The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Seeking Alpha analysts Stephen Ayers ...
09-14 04:18
Cantor Fitzgerald Reiterates Overweight on Septerna, Maintains $25 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Septerna (NASDAQ:SEPN) with a Overweight and maintains $25 price target.
09-05 21:52
美股牛股 | 绩优股狂飙！梅西百货大涨超20%，REV Group涨超12%；房地美ADR涨超16%
绩优股狂飙！梅西百货大涨超20%，REV Group涨超12%；房地美ADR涨超16%，美参议院议员敦促特朗普政府暂缓出售公司股份>>
09-04 17:12
诺和诺德扳回一局，称减重版司美格鲁肽心血管获益优于替尔泊肽
在GLP-1（胰高血糖素样肽-1）减肥药的竞争中，诺和诺德的司美格鲁肽终于凭借心血管方面的获益扳回一局。 9月1日，澎湃新闻记者从诺和诺德中国获悉，该公司在西班...
09-01 14:32
Septerna to Participate in Upcoming Investor Conferences
Septerna, Inc., a clinical-stage biotech company focused on GPCR drug discovery, announced its participation in two upcoming investor conferences in September: the Cantor Global Healthcare Conference 2025 on September 3, 2025, and the 2025 Wells Fargo Healthcare Conference on September 5, 2025. Live webcasts and replays of the presentations will be available on the company’s website. Septerna specializes in advancing GPCR therapies using its prop...
08-27 12:00
Septerna Begins Phase 1 Trial for SEP-631
The latest announcement is out from Septerna, Inc. ( ($SEPN) ). On August 21, 2...
08-21 20:58
Septerna Announces Dosing Of First Participants In Phase 1 Clinical Trial Of SEP-631, Selective Oral Small Molecule MRGPRX2 NAM Being Developed For Treatment Of CSU And Other Mast Cell-Driven Diseases
Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical
08-21 20:08
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Septerna, Inc. has initiated a Phase 1 clinical trial for SEP-631, a novel oral treatment targeting chronic spontaneous urticaria and mast cell-driven diseases. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-631 in healthy volunteers. As a selective negative allosteric modulator of MRGPRX2, SEP-631 inhibits mast cell activation and degranulation, offering potential relief for millions affected b...
08-21 12:00
跨国药企洞察｜左手诉讼 右手创新 发起132诉讼的诺和诺德能否赢得“反击战”？
（来源：动脉新医药） 编者按： 全球视野下的跨国药企深度洞察——创新、博弈与中国答卷 在全球医药产业发展的宏大叙事中，跨国药企始终扮演着关键角色——他们...
08-15 17:54
